Raza and colleagues, using a multidimensional fractionation strategy of pooled plasma samples from AML patients in comparison with those from healthy controls, reported an increase in SAA1 expression, and this protein could be used as a potential biomarker for AML [45]. The gene discussed is SAA1; the disease is acute myeloid leukemia.